{"brief_title": "GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin", "brief_summary": "The purpose of this study is to determine the efficacy of an oral investigational drug in patients with refractory metastatic colorectal cancer after receiving prior therapy with 5-fluorouracil in combination with irinotecan and/or oxaliplatin.", "condition": "Colorectal Cancer", "intervention_type": "Drug", "intervention_name": "lapatinib", "criteria": "Inclusion Criteria: - Provide signed informed consent. - Refractory Stage IV metastatic colorectal cancer. - Received at least 2 cycles of first-line therapy with intravenous 5-FU (5-fluorouracil) in combination with CPT-11 (irinotecan) and/or oxaliplatin. - No more than one prior therapy. - Tumor tissue available for testing. - 4 weeks since first-line cancer regimen. - Able to swallow and retain oral medication. - Cardiac ejection fraction within the institutional range of normal as measured by MUGA (Multiple Gated Acquisition Scan). - Adequate kidney and liver function. - Adequate bone marrow function. Exclusion Criteria: - Pregnant or lactating female. - Conditions that would affect absorption of an oral drug - First-line regimen did not include 5-fluorouracil with irinotecan and/or oxaliplatin. - Serious medical or psychiatric disorder that would interfere with the patient''s safety or informed consent. - Severe cardiovascular disease or cardiac (heart) disease requiring a device. - Active infection. - Brain metastases. - Concurrent cancer therapy or investigational therapy. - Use of oral or intravenous steroids. - Unresolved or unstable, serious toxicity from prior therapy. - Prior therapy with an EGFR (Endothelial Growth Factor Receptor) and/or erbB-2 inhibitor.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00044343.xml"}